Figure 4. Monotherapy with vPD1 can eradicate established melanomas.

(A–C) C57/B6 mice were injected SQ with 4x10⁵ B16/F10 cells. On day 7 post injection, mice were randomly separated into one of four cohorts: saline + isotype (n=12), vGFP + isotype (n=10), vGFP + αPD1 antibody (n=17), or vPD1 (n=22). Viral injections consisted of 1x10⁷ FFU of MYXV and were given on days 7, 9, and 11. Antibody injections consisted of 100μg/injection and were given on days 7, 11, 14, and 18. (A) Animals were monitored for tumor burden and euthanized when tumors reached 15mm in any direction. Data represents summation of four independent experiments. Significance was determined using log-rank test. (B) Average overall response rates for each treatment group (defined as the number of animals surviving when the last saline treated animal was euthanized). Significance was determined by averaging response rates from four experiments and analyzing using unpaired students T-Test. (C) Average complete response rates for each treatment group (defined as animals displaying no remaining tumor burden 80 days post treatment). Significance was determined by averaging response rates from four experiments and analyzing using unpaired students T-Test. (D) Average alopecia score from vGFP + αPD1 antibody (n=12) and vPD1 (n=22) treated animals. * denotes significance of p<0.05 for the indicated day and was determined using unpaired students T-Test. (E) Example of alopecia in mice on day 70 post treatment. Abbreviations: OR (overall response), CR (compete response).